Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Joshua Evans

Gastroenterology Omaha, NE Medical Doctor

NPI 1861579450 CMS profile 84074

8901 Indian Hills Dr, Suite 200, Omaha, NE 68114

Open in the dashboard

General payments

$33,720

207 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Joshua Evans of Omaha, NE is reported in the CMS Open Payments database as having received $33,720 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $61 4
2022 General $4,907 61
2021 General $7,388 57
2020 General $11,980 34
2019 General $9,384 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Evans
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Joshua Evans were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Joshua Evans Gastroenterology median Middle half National median
2019 $9,384 $417 $126–$1,100 $163
2020 $11,980 $224 $74–$624 $114
2021 $7,388 $352 $106–$1,054 $132
2022 $4,907 $448 $129–$1,270 $149
2023 $61 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $29,945 114 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,273 15 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $435 24 payments
  4. QOL Medical, LLC $313 17 payments
  5. Celgene Corporation $280 6 payments
  6. Janssen Biotech, Inc. $184 15 payments
  7. Gilead Sciences, Inc. $81 4 payments
  8. Genzyme Corporation $46 2 payments
  9. Intercept Pharmaceuticals, Inc. $45 3 payments
  10. Ironwood Pharmaceuticals, Inc $23 1 payment
  11. Other $94 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,000 16 payments
  2. Food and Beverage $3,378 179 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,000 1 payment
  4. Travel and Lodging $1,294 8 payments
  5. Debt forgiveness $30 2 payments
  6. Consulting Fee $18 1 payment
Products named General payments · program years 2019–2023
  1. CREON $4,688 63 payments
  2. XIFAXAN $2,215 12 payments
  3. Sucraid $313 17 payments
  4. ZEPOSIA $280 6 payments
  5. ENTYVIO Internal Medicine $215 12 payments
  6. HUMIRA $185 12 payments
  7. STELARA $184 15 payments
  8. Entyvio Lower GI $153 9 payments
  9. LINZESS $145 10 payments
  10. SIMPONI ARIA $92 6 payments
  11. Other $673 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record